Stifel lowered the firm’s price target on Nurix Therapeutics (NRIX) to $34 from $35 and keeps a Buy rating on the shares after the company reported a GAAP net loss that was wider than the firm’s and consensus estimates, primarily driven by the recognition of lower-than-expected collaborative revenue. Registrational bexobrutideg development plans in CLL continue to progress, with patient enrollment into the Phase 2 DAYBreak CLL-201 trial ongoing and initiation of the confirmatory Phase 3 DAYBreak CLL-306 now anticipated to begin enrolling patients in mid-2026, the analyst noted.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRIX:
- Nurix Therapeutics: Buy Rating Backed by Advancing Bexobrutideg Program, Sanofi STAT6 Milestones, and Solid Cash Runway
- Nurix Advances NX-5948 Into Phase 3 Head-to-Head Battle in CLL/SLL
- Midday Fly By: Delta reports Q1 beat, Bed Bath & Beyond to buy F9 Brands
- Nurix Therapeutics reports Q1 EPS (79c), consensus (76c)
- Nurix Therapeutics Expands ATM Equity Offering Capacity